Эрфлюсал (Fluticasone Propionate/Salmeterol) is commonly used across domains where additional symptomatic support is needed for symptom control, relevant in contexts involving heightened systemic burden due to chronic respiratory conditions.

This combination is relevant for easing symptom groups that interfere with daily comfort, such as persistent wheezing, shortness of breath, and chest tightness. It is commonly used across conditions presenting with Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and emphysema, and for the regular treatment of persistent asthma in patients aged 4 years and older.

The medication is commonly used in situations where previous symptom management with a single inhaled corticosteroid has not been sufficient to achieve stability. It is considered relevant for managing the risk of acute exacerbations (flare-ups) in patients with COPD who have a history of such events. This essential prophylactic (preventative) role may assist with maintaining functional stability and supports patients during episodes of heightened discomfort.

“It provides continuous therapeutic support, which contributes to easing the overall symptom load and may help patients cope more steadily with symptom fluctuations.”

---

Quick Fact: Relief for Persistent Breathing Difficulties

Property	Description
Primary Indication	Long-term maintenance for Persistent Asthma and COPD (Chronic Obstructive Pulmonary Disease)
Symptom Focus	Persistent wheezing, shortness of breath, and chest tightness
Use Scenario	Daily maintenance therapy to manage the risk of exacerbations and support stability when monotherapy is insufficient
Key Benefit	Supports functional stability and helps ease the overall symptom burden

Regulatory References

1. NIH DailyMed drug label

Who Can and Cannot Use Эрфлюсал (Fluticasone Propionate/Salmeterol)

Official regulatory documents define strict criteria for the use of this medicine, focusing on age, acute health status, and pre-existing conditions.

---

Contraindications and Restrictions

Category	Regulatory Status
Absolute Contraindication	The medicine is contraindicated for patients with a known history of hypersensitivity to Fluticasone Propionate, Salmeterol, or any excipient (e.g., milk protein). It must not be used for acute episodes of asthma or COPD (like status asthmaticus) or by patients currently using another Long-Acting beta2-Adrenergic Agonist (LABA).
Age Restriction	Use is not established in pediatric patients younger than 4 years of age. The COPD indication is restricted to adult patients (aged 18 years and older).
Conditional Caution	Caution is required for populations with pre-existing conditions, including hepatic impairment (requires monitoring), tuberculosis or other systemic infections, and significant cardiovascular disorders.

---

Approved Population

Эрфлюсал is approved for the regular maintenance treatment of asthma in patients aged 4 years and older, and for the maintenance treatment of COPD in adult patients. Regulatory labeling notes that the status for use during pregnancy and lactation must be considered based on specific clinical context.

Interactions with other medicines and products

This section outlines the officially documented interaction profile of Эрфлюсал (Fluticasone Propionate/Salmeterol), based strictly on regulatory prescribing information.

Classification	Interacting Agents and Context	Regulatory Description
Contraindicated	Other Long-Acting Beta2-Agonists (LABAs)	Formal prohibition of co-administration due to the documented risk of overdose.
Not Recommended	Strong Cytochrome P450 3A4 (CYP3A4) Inhibitors (e.g., Ritonavir, Ketoconazole)	Increases systemic exposure of both active components, posing a risk of systemic corticosteroid and cardiovascular effects.
Caution Advised	Beta-Blockers (selective and non-selective)	May block the bronchodilatory effects of Salmeterol, risking severe bronchospasm.
Caution Advised	MAOIs, TCAs, and Non-Potassium-Sparing Diuretics	May potentiate Salmeterol’s vascular effects or worsen hypokalemia (low potassium) and associated electrocardiographic changes.

Population-Specific Caution: Regulatory documents advise caution in patients with Hepatic Impairment (liver disease) due to the potential for reduced clearance, which may lead to accumulation of Fluticasone in plasma. A food interaction is also noted, as Grapefruit Juice may increase exposure due to CYP3A4 inhibition.

How AirFluSal Works

AirFluSal, a combination formulation, exerts its effects through two distinct, non-overlapping pharmacodynamic mechanisms that modulate cellular activity and muscle tone within the airways.

Glucocorticoid Receptor-Mediated Signaling Modulation

One component (Fluticasone Propionate) engages intracellular glucocorticoid receptors. This binding leads to the altered transcription of genes, primarily suppressing the expression of pro-inflammatory mediators such as cytokines, chemokines, and certain hydrolytic enzymes. The resultant intracellular consequence is the reduced migration and accumulation of inflammatory cells and fluid in the respiratory tract walls, modifying local tissue processes.

Sustained beta2-Adrenoceptor Activation

The second component (Salmeterol) functions as a long-acting agonist, selectively targeting and binding to beta2-adrenoceptors on airway smooth muscle cells. This interaction initiates a signaling cascade that increases the intracellular concentration of cyclic AMP (cAMP). This biochemical change reduces the intracellular calcium level and modifies the contractile state of the smooth muscle. The system-level physiological consequence of this mechanism is prolonged bronchodilation, or the sustained widening of the bronchioles.

Official Administration Instructions

Эрфлюсал is an inhalation powder administered via an inhalation device (dry powder inhaler, DPI) for oral use. All instructions for its use are strictly defined to ensure proper delivery of the medicine to the lungs.

Usage Domain	Administration Guidance
Route & Frequency	Oral inhalation. The standard dose for adults and adolescents 12 years and older is one inhalation twice daily (morning and evening), approximately 12 hours apart.
Missed Dose	If a dose is missed, skip the missed dose and take the next dose at the regular scheduled time. Do not take a double dose to make up for the missed one.
Dose Preparation	Immediately before inhalation, the dose must be prepared by opening the protective cap, lifting the white lever fully over until it clicks, and then closing the white lever fully until it clicks back into place.
Post-Inhalation Care	After inhaling the medicine, the user must rinse the mouth with water and spit it out. This is a required step following each use.

---

Inhalation Procedure

The user must exhale gently and slowly away from the inhaler before placing their lips firmly around the mouthpiece (without blocking the air inlets). The dose should then be taken with a steady and deep breath through the inhaler. Following inhalation, the breath must be held for 5 to 10 seconds, or for as long as comfortably possible, before breathing out slowly away from the device. The instructions also mandate checking the dose counter when opening the protective cap, and the device is not recommended for use in children under 12 years.

Research Evidence / Overview of Studies for Эрфлюсал

Evidence for use in Chronic Obstructive Pulmonary Disease (COPD)

Research has evaluated Эрфлюсал in patients managing COPD, a condition marked by functional limitations and conditions presenting with cycles of stability and flare-ups. Studies examined how studies evaluated long-term lung function measurements and how studies monitored outcomes describing episodic or acute changes (known as exacerbations). This evidence is primarily derived from controlled trials.

The main outcomes reflecting daily functioning or activity level was studied for their relationship with the use of Эрфлюсал. Some clinical studies describe patterns related to changes measured in certain lung capacity measurements. Data show patterns related to fewer such episodes observed in the treatment group compared to the control groups.

Evidence for use in Asthma: Maintenance

The use of Эрфлюсал was studied for outcomes reflecting daily functioning and activity level in patients with asthma, particularly in adults and adolescents whose conditions are characterized by fluctuating or episodic manifestations. The research focused on outcomes related to physical discomfort and measurements of inflammation. Clinical trials explored whether consistent use of the medicine was observed in studies exploring how symptoms change over time.

Long-term Studies and Follow-up

Research looking at the effects of Эрфлюсал over extended-duration time periods is a critical area, but also one where evidence is limited. Most controlled trials observed responses over defined time intervals of a few months to a year, which means that there is limited information for long-term outcomes regarding how the changes measured during the study period evolve. Long-term effects are not fully established beyond that window.

Evidence in Special Populations

The use of Эрфлюсал was evaluated in a few specific groups. Studies focusing on younger individuals are often more limited than those for adults. Evidence describes patterns of how symptoms change in this age group, but sample sizes were modest, and the data for certain groups remain insufficient to draw wide-ranging conclusions. Research has explored patterns of response in older adults and those with other health issues (comorbid conditions).

What is Still Uncertain about Эрфлюсал

The evidence base for Эрфлюсал is not complete, and this section synthesizes the areas where evidence highlights what is known — and what is still uncertain. Key uncertainties include the precise role of Эрфлюсал in combination with all other available therapies, as comparative evidence is lacking for certain combinations. Findings describe group patterns, not personal outcomes, and it is uncertain which individual patients are most likely to observe changes measured during the study period.

Common questions about Эрфлюсал (FAQ)

---

Q: How do I prepare the inhaler before I take a puff?

A: Product instructions specify the dose should be prepared immediately before inhalation. This preparation often involves specific mechanical steps, such as operating a lever until a click is heard, and then closing it. The official instructions include specific steps for preparation and inhalation, which are important for proper use.

---

Q: What is the risk of using this medicine long-term?

A: Regulatory documents indicate that long-term use of the inhaled corticosteroid component may be associated with certain systemic effects. These effects can include possible adrenal suppression, a decrease in bone mineral density, and the potential development of cataracts or glaucoma. Patients are generally advised to discuss any concerns about long-term use and potential monitoring with their healthcare provider.

---

Q: What is the latest an adult can use this medicine before bed if they take it at 8 AM?

A: The medicine is generally prescribed for twice-daily administration. Official product information recommends that the doses be taken approximately 12 hours apart to help maintain consistent therapeutic levels. Consult the full administration guidelines or your prescriber for clarity on scheduling your doses.

---

Q: Is it okay to use this inhaler if I am pregnant?

A: Official documents state there are limited human data regarding the possible effects of this medicine during pregnancy. Therefore, the medication is generally considered only if the expected benefit to the mother is judged to outweigh any potential risk to the developing fetus. Decisions about using the medicine during pregnancy are based on a risk-benefit assessment by a healthcare professional.

---

Q: When will I start feeling better after starting this inhaler?

A: This medication is designed for long-term maintenance rather than immediate relief. Official product information for the components indicates that the onset of the full therapeutic effect is typically within four to seven days. Clinical studies suggest an initial benefit may be observed as early as 24 hours in some individuals, particularly those new to inhaled steroids.

---

Q: Does this medicine contain milk protein?

A: The inhalation powder formulation of this medicine contains lactose monohydrate. Since lactose is derived from milk, official documents for some similar products note a specific contraindication for individuals with a known, severe allergy to milk proteins. Individuals with concerns about a milk protein allergy should refer to the full ingredient list and discuss it with a healthcare professional.

---

Q: How do I know when the inhaler is empty and needs to be replaced?

A: The device features a built-in dose counter to track the number of doses remaining. The device is typically discarded when the counter displays '0' or one month after it is first removed from the foil pouch, whichever occurs first. Some inhalers are designed to display a change in color, such as a red indicator, when only a few doses remain.

---

How to Store and Dispose of Эрфлюсал?

The official storage and disposal requirements for Эрфлюсал are designed to maintain the stability of the inhalation powder or aerosol and ensure safety.

---

Official Storage Conditions

Requirement	Details
Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Container & Environment	Keep the device in a dry place, away from direct heat, sunlight, and moisture. Store in the unopened foil pouch until first use.
Prohibitions	Do not freeze the aerosol canister. Do not wash the inhaler device.
Stability	Discard the device 1 month after removing it from the foil pouch, or when the dose counter reads “0,” whichever comes first.
Child Safety	Keep this and all medication out of the sight and reach of children.

Disposal Instructions

Discard used or empty inhalers safely in the household trash. Do not puncture the aerosol canister or dispose of it in a fire. Consult a pharmacist for guidance on the proper disposal of any unused or expired product.